Nurix Therapeutics (NRIX) Current Assets (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Current Assets data on file, last reported at $456.5 million in Q2 2026.

• On a quarterly basis, Current Assets fell 11.42% year-over-year to $456.5 million in Q2 2026; TTM through May 2026 was $456.5 million, a 11.42% decrease from a year earlier, with the FY2025 full-year figure at $606.8 million, down 2.03% from the prior year.
• Current Assets for Q2 2026 stood at $456.5 million, down from $554.4 million in the prior quarter.
• Over the last five years, Current Assets for NRIX reached as high as $619.4 million in Q4 2024 and fell as low as $251.0 million in Q1 2024.
• Historically, Current Assets has averaged $406.5 million across 5 years, with a median of $397.7 million in 2022.
• Across the five-year window, Current Assets retreated 24.49% in 2023 and surged 124.61% in 2025, its largest moves.
• Year by year, Current Assets stood at $318.4 million in 2022, then dropped by 7.21% to $295.5 million in 2023, then surged by 109.6% to $619.4 million in 2024, then declined by 2.03% to $606.8 million in 2025, then retreated by 24.77% to $456.5 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $456.5 million in Q2 2026, $554.4 million in Q1 2026, and $606.8 million in Q4 2025.